Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Anna Schuh et al.|New England Journal of Medicine|2015Cited by 890
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilityBrian J. Lannutti, Neill A. Giese|Blood|2010Cited by 717
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemiaMatthew S. Davids, Anthony Letai, Jing Deng et al.|Blood|2012Cited by 132